Targeting cells which were dependent on GLUT3 by interfering with integrin and PAK4-YAP/TAZ signaling reduced GLUT3 expression and tumor cell viability, introducing a novel approach to treat this aggressive tumor type (41). The gene discussed is SLC2A3; the disease is neoplasm.